PL3412664T3 - Heterocykliczna pochodna sulfonamidowa i lek zawierający tę pochodną - Google Patents

Heterocykliczna pochodna sulfonamidowa i lek zawierający tę pochodną

Info

Publication number
PL3412664T3
PL3412664T3 PL17747613T PL17747613T PL3412664T3 PL 3412664 T3 PL3412664 T3 PL 3412664T3 PL 17747613 T PL17747613 T PL 17747613T PL 17747613 T PL17747613 T PL 17747613T PL 3412664 T3 PL3412664 T3 PL 3412664T3
Authority
PL
Poland
Prior art keywords
containing same
medicine containing
sulfonamide derivative
heterocyclic sulfonamide
heterocyclic
Prior art date
Application number
PL17747613T
Other languages
English (en)
Inventor
Kaori Kobayashi
Tamotsu Suzuki
Tatsuya Okuzumi
Original Assignee
Ea Pharma Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ea Pharma Co., Ltd. filed Critical Ea Pharma Co., Ltd.
Publication of PL3412664T3 publication Critical patent/PL3412664T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL17747613T 2016-02-05 2017-02-03 Heterocykliczna pochodna sulfonamidowa i lek zawierający tę pochodną PL3412664T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016021358 2016-02-05
PCT/JP2017/004134 WO2017135462A1 (ja) 2016-02-05 2017-02-03 複素環スルホンアミド誘導体及びそれを含有する医薬
EP17747613.2A EP3412664B1 (en) 2016-02-05 2017-02-03 Heterocyclic sulfonamide derivative and medicine containing same

Publications (1)

Publication Number Publication Date
PL3412664T3 true PL3412664T3 (pl) 2022-06-06

Family

ID=59499709

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17747613T PL3412664T3 (pl) 2016-02-05 2017-02-03 Heterocykliczna pochodna sulfonamidowa i lek zawierający tę pochodną

Country Status (14)

Country Link
US (1) US10584116B2 (pl)
EP (1) EP3412664B1 (pl)
JP (1) JP6906449B2 (pl)
KR (1) KR102766396B1 (pl)
CN (1) CN108602807B (pl)
AU (1) AU2017213993B2 (pl)
CA (1) CA3012812A1 (pl)
DK (1) DK3412664T3 (pl)
EA (1) EA037264B1 (pl)
ES (1) ES2911416T3 (pl)
MA (1) MA43978A (pl)
MX (1) MX379373B (pl)
PL (1) PL3412664T3 (pl)
WO (1) WO2017135462A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7043483B2 (ja) * 2016-07-20 2022-03-29 エフ.ホフマン-ラ ロシュ アーゲー 二環式プロリン化合物
FR3114235A1 (fr) 2020-09-18 2022-03-25 Université Grenoble Alpes Inhibition du canal trpa1 astrocytaire comme nouvelle cible therapeutique neuroprotectrice dans les phases prodromales de la maladie d’alzheimer
IT202100015098A1 (it) 2021-06-09 2022-12-09 Flonext S R L Composto antagonista del canale trpa1 per uso in patologie degenerative della retina
WO2023033097A1 (ja) * 2021-09-02 2023-03-09 Eaファーマ株式会社 複素環スルホンアミド誘導体の製造方法、およびその合成中間体
EP4617267A4 (en) * 2022-11-10 2026-02-18 Prime Gene Therapeutics Co Ltd Thioether compound having mild medicinal properties and its use, pharmaceutical composition and associated uses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017612B2 (en) * 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
US8614201B2 (en) 2009-06-05 2013-12-24 Janssen Pharmaceutica Nv Heterocyclic amides as modulators of TRPA1
EP2520566A1 (en) * 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
CN104203236A (zh) * 2012-01-17 2014-12-10 味之素株式会社 杂环酰胺衍生物和含有其的药物
AR092684A1 (es) 2012-09-27 2015-04-29 Hoffmann La Roche Compuestos de sulfonamida sustituidos
CN104854086B (zh) 2012-12-18 2017-06-27 Ea制药株式会社 杂环酰胺衍生物和含有其的药物
EP2774919A1 (en) * 2013-03-06 2014-09-10 Pharmeste S.R.L. In Liquidazione Novel sulfonamide TRPA1 receptor antagonists
HUE041652T2 (hu) * 2013-10-11 2019-05-28 Hoffmann La Roche TRPA1-modulátorokként hasznos szubsztituált heterociklusos szulfonamid-vegyületek
CN106458952B (zh) 2014-01-28 2019-09-27 Ea制药株式会社 杂环磺酰胺衍生物及含有所述杂环磺酰胺衍生物的药物
WO2016128529A1 (en) 2015-02-15 2016-08-18 F. Hoffmann-La Roche Ag 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists
WO2017018495A1 (ja) * 2015-07-29 2017-02-02 Eaファーマ株式会社 シクロプロパン誘導体及びそれを含有する医薬

Also Published As

Publication number Publication date
EP3412664B1 (en) 2022-03-30
MA43978A (fr) 2018-12-12
JPWO2017135462A1 (ja) 2018-12-13
MX379373B (es) 2025-03-10
CN108602807B (zh) 2022-05-13
EP3412664A4 (en) 2019-10-16
US20190023699A1 (en) 2019-01-24
BR112018015851A2 (pt) 2018-12-26
EA037264B1 (ru) 2021-03-01
KR102766396B1 (ko) 2025-02-13
AU2017213993B2 (en) 2021-03-25
CA3012812A1 (en) 2017-08-10
WO2017135462A1 (ja) 2017-08-10
JP6906449B2 (ja) 2021-07-21
KR20180104150A (ko) 2018-09-19
EA201891782A1 (ru) 2019-06-28
US10584116B2 (en) 2020-03-10
MX2018009458A (es) 2018-09-21
DK3412664T3 (da) 2022-06-07
EP3412664A1 (en) 2018-12-12
AU2017213993A1 (en) 2018-09-13
ES2911416T3 (es) 2022-05-19
CN108602807A (zh) 2018-09-28

Similar Documents

Publication Publication Date Title
IL289276A (en) Treprostinil derivatives and compositions and uses thereof
ZA202001340B (en) Heterocyclic compound and use thereof
IL258180B (en) Heterocyclic compounds and their uses
IL252560B (en) Heterocyclic derivatives and their uses
EP3101015A4 (en) Heterocyclic sulfonamide derivative and medicine comprising same
PL3412660T3 (pl) Pochodna sulfonamidowa i zawierająca ją kompozycja farmaceutyczna
IL253538A0 (en) Heterocyclic compound and pharmaceutical compound containing it
PL3287443T3 (pl) 6-członowa pochodna heterocykliczna i kompozycja farmaceutyczna ją zawierająca
SG11201606902QA (en) Triazine compound and use thereof for medical purposes
IL248744A0 (en) History of heterocyclic butanamides, their preparation and drugs containing them
EP3197885A4 (en) Heterocyclic compounds and use thereof
SG11201610407QA (en) Aromatic heterocyclic derivatives and pharmaceutical applications thereof
IL274225A (en) Heterocyclic anti-pollution compounds and their uses
ZA201607919B (en) Dipicolylamine derivatives and their pharmaceutical uses
EP3412664A4 (en) Heterocyclic sulfonamide derivative and drug with it
IL263651A (en) Anti-pollution heterocyclic compounds and their uses
EP3134392A4 (en) Sulfonamide derivatives and pharmaceutical applications thereof
PT3646864T (pt) Medicamento contendo pemafibrato
SG11202100027RA (en) Heterocyclic sulfonamide derivatives and pharmaceutical uses thereof
GB201610823D0 (en) Heterocyclic compounds and medical uses
HK40007516A (zh) 抗感染杂环化合物及其用途
SI3224253T1 (sl) Derivati bis(sulfonamida) in njihova uporaba kot zaviralci MPGES
AU2014901768A0 (en) Heterocyclic compounds and use of same
AU2015902830A0 (en) Heterocyclic compounds and methods for their use
AU2015901751A0 (en) Heterocyclic Compounds And Methods For Their Use